NewAmsterdam Pharma Co N.V. financial data

Symbol
NAMS, NAMSW on Nasdaq
Location
Narrden, Netherlands
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 18 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1352% % 53%
Debt-to-equity 7.5% % -52%
Return On Equity -27% % 45%
Return On Assets -26% % 41%
Operating Margin -1003% % -159%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 114,975,422 shares
Common Stock, Shares, Outstanding 114,399,326 shares 5.9%
Entity Public Float $1,345,893,076 USD 28%
Common Stock, Value, Issued $14,278,000 USD 6.2%
Weighted Average Number of Shares Outstanding, Basic 118,424,231 shares 26%
Weighted Average Number of Shares Outstanding, Diluted 118,424,231 shares 26%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $22,503,000 USD -51%
Research and Development Expense $141,832,000 USD -6.3%
General and Administrative Expense $15,374,000 USD 6.5%
Operating Income (Loss) $225,683,000 USD -28%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $203,819,000 USD 16%
Income Tax Expense (Benefit) $1,000 USD
Net Income (Loss) Attributable to Parent $203,819,000 USD 16%
Earnings Per Share, Basic -1.72 USD/shares 33%
Earnings Per Share, Diluted -1.72 USD/shares 33%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $490,002,000 USD -37%
Marketable Securities, Current $146,239,000 USD 134%
Assets, Current $675,700,000 USD -22%
Property, Plant and Equipment, Net $383,000 USD 58%
Operating Lease, Right-of-Use Asset $185,000 USD -57%
Assets $769,284,000 USD -11%
Accounts Payable, Current $8,970,000 USD 89%
Liabilities, Current $85,787,000 USD -20%
Operating Lease, Liability, Noncurrent $66,000 USD -67%
Liabilities $85,853,000 USD -20%
Accumulated Other Comprehensive Income (Loss), Net of Tax $4,793,000 USD 7.3%
Retained Earnings (Accumulated Deficit) $762,390,000 USD -36%
Stockholders' Equity Attributable to Parent $683,431,000 USD -9.8%
Liabilities and Equity $769,284,000 USD -11%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $36,468,000 USD 33%
Net Cash Provided by (Used in) Financing Activities $6,519,000 USD -97%
Net Cash Provided by (Used in) Investing Activities $2,855,000 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 114,399,326 shares 5.9%
Common Stock, Par or Stated Value Per Share 0.12 EUR/shares 0%
Deferred Tax Assets, Valuation Allowance $217,005,000 USD 18%
Deferred Tax Assets, Gross $217,048,000 USD 17%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $203,493,000 USD 16%
Operating Lease, Liability, Current $136,000 USD -45%
Deferred Tax Assets, Operating Loss Carryforwards $128,873,000 USD -3.5%
Unrecognized Tax Benefits $0 USD
Depreciation, Depletion and Amortization $52,000 USD 247%
Deferred Tax Assets, Net of Valuation Allowance $43,000 USD -59%
Share-based Payment Arrangement, Expense $59,425,000 USD 77%